Valuation: VISEN Pharmaceuticals

Market Cap 1.29B 1.52B 194M 174M 160M 145M 271M 18.43B 276M 1.91B 765M 9.69B 728M 713M 30.57B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.03B 1.21B 155M 139M 127M 115M 216M 14.68B 220M 1.52B 610M 7.72B 580M 568M 24.36B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 4.04x
Free-Float
28.04%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-8.36%
1 month-25.59%
3 months-27.67%
6 months-47.83%
Current year-57.53%
1 week 12.87
Extreme 12.87
16.01
1 month 12.87
Extreme 12.87
19.9
Current year 12.87
Extreme 12.87
43.3
1 year 12.87
Extreme 12.87
43.3
3 years 12.87
Extreme 12.87
69.15
5 years 12.87
Extreme 12.87
69.15
10 years 12.87
Extreme 12.87
69.15
Manager TitleAgeSince
Chief Executive Officer 60 07/11/2018
Director of Finance/CFO 42 13/10/2025
Chief Tech/Sci/R&D Officer 54 01/04/2020
Director TitleAgeSince
Director/Board Member 60 07/11/2018
Director/Board Member 44 08/01/2021
Director/Board Member 62 01/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/1/26 Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-8.36%-63.36% - 194M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.26%+5.95%+36.48%+194.99% 39.45B
Weighted average by Cap. +0.18%+5.44%+47.94%+176.67%

Financials

2026 *2027 *
Net sales 67.73M 79.84M 10.18M 9.11M 8.38M 7.6M 14.2M 966M 14.47M 99.98M 40.13M 508M 38.19M 37.38M 1.6B 320M 377M 48.05M 43.03M 39.58M 35.87M 67.04M 4.56B 68.3M 472M 189M 2.4B 180M 176M 7.57B
Net income - -
Net Debt -262M -309M -39.41M -35.3M -32.47M -29.42M -54.99M -3.74B -56.02M -387M -155M -1.97B -148M -145M -6.21B 486K 573K 73.03K 65.41K 60.16K 54.51K 102K 6.93M 104K 717K 288K 3.65M 274K 268K 11.5M
Projected Income Statement - Annual - VISEN Pharmaceuticals
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
102
Date Price Change Volume
30/10/26 HK$13.93 -0.50% 28,000
29/10/26 HK$14.00 -1.96% 15,700
28/10/26 HK$14.28 -4.80% 2,400
27/10/26 HK$15.00 -3.23% 9,500
26/10/26 HK$15.50 +1.97% 14,400
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
11.82CNY
Average target price
42.85CNY
Spread / Average Target
+262.58%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - VISEN Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. 2561 Stock